Liu, Tiantian <br/><br/>
Low molecular-weight fucoidan protects against hindlimb ischemic injury in type 2 diabetic mice through enhancing endothelial nitric oxide synthase phosphorylation.  [electronic resource] 

 -  Journal of diabetes  Nov 2018 
 - 820-834 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1753-0407 
<br/><br/><label>Standard No.: </label>10.1111/1753-0407.12667  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inducing Agents--pharmacology<br/>Animals<br/>Cells, Cultured<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Diabetic Angiopathies--enzymology<br/>Disease Models, Animal<br/>Hindlimb<br/>Human Umbilical Vein Endothelial Cells--drug effects<br/>Humans<br/>Ischemia--enzymology<br/>Mice, Inbred C57BL<br/>Molecular Weight<br/>Muscle, Skeletal--blood supply<br/>Neovascularization, Physiologic--drug effects<br/>Nitric Oxide--metabolism<br/>Nitric Oxide Synthase Type III--metabolism<br/>Phosphorylation<br/>Polysaccharides--pharmacology<br/>Signal Transduction--drug effects<br/>Vascular Endothelial Growth Factor A--metabolism